Mydriasis Market to Expand Significantly by 2034, States DelveInsight Report

DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Mydriasis, offering comprehensive insights into the Mydriasis revenue trends, prevalence, and treatment landscape. The report delves into key Mydriasis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Mydriasis therapies. Additionally, we cover the landscape of Mydriasis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Mydriasis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Mydriasis space.

To Know in detail about the Mydriasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mydriasis Market Forecast
https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Mydriasis Market Report:
• The Mydriasis market size was valued ~USD 604 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In September 2024, Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company specializing in the development and commercialization of small molecule therapies for retinal and refractive eye conditions, has announced the publication of complete results from its two pivotal Phase 3 trials, MIRA-2 and MIRA-3. These studies assessed the safety and effectiveness of RYZUMVITM (Phentolamine Ophthalmic Solution 0.75%) for treating pharmacologically-induced mydriasis, with the findings published in the peer-reviewed journal Ophthalmology.
• In 2023, the total market size for Mydriasis in the US was around USD 378.6 million, representing approximately 63% of the overall market revenue across the 7MM.
• In 2023, the total market size for Mydriasis in EU4 and the UK was estimated to be around USD 150.4 million. Germany held the largest share with approximately USD 42.7 million, followed by France with USD 36.5 million, and the UK with USD 28.3 million.
• In 2023, the market size for Mydriasis in Japan was estimated to be around USD 75.4 million.
• In 2023, the largest market share among current therapies was held by topical treatments (eye drops/irrigation) for surgeries, generating around USD 286.2 million in the 7MM. This was followed by topical treatments (eye drops/irrigation) for eye exams, with a revenue of approximately USD 183.5 million, and OMIDRIA, which earned approximately USD 112.1 million.
• Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others
• Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others
• The Mydriasis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mydriasis pipeline products will significantly revolutionize the Mydriasis market dynamics.
• DelveInsight's epidemiology model estimates that there were around 352.1 million eye examinations and ophthalmic surgeries in the 7MM in 2023. This number is projected to grow over the forecast period (2024-2034), driven by the increasing prevalence of age-related eye conditions like cataracts, glaucoma, and macular degeneration, which are expected to result in a higher demand for eye exams and surgeries.
• In 2023, out of the total eye examinations and ophthalmic surgeries in the 7MM, around 338.0 million were eye exams and check-ups. Additionally, there were approximately 8.6 million cataract surgeries, 538 thousand glaucoma surgeries, 1.6 million refractive surgeries, 505 thousand vitreoretinal surgeries, and 2.9 million cases involving other types of surgeries.
• In 2023, the US made up 53% of the total eye examinations and ophthalmic surgeries, while EU4 and the UK accounted for 32%, and Japan contributed 15% of the cases.
• In 2023, there were around 65.1 million instances of pupil dilation for eye examinations and approximately 5.1 million cases for eye surgeries in the EU4 countries and the UK.
• In 2023, Germany led the EU4 and the UK with the highest number of pupil dilation cases, recording 16.7 million for eye examinations and 1.5 million for surgeries. France followed with about 13.5 million cases for eye examinations and 1.3 million for surgeries. Spain had the lowest figures, with 9.3 million pupil dilation cases for eye exams and 634 thousand for surgeries.
• In 2023, Japan recorded approximately 29.7 million cases of pupil dilation for eye examinations and around 2.5 million cases for eye surgeries. These figures are anticipated to shift throughout the forecast period.

Mydriasis Overview
Mydriasis refers to the dilation of the pupils, which can occur naturally or be induced for medical purposes. It is commonly achieved through the use of mydriatic agents (eye drops or irrigation solutions) during eye examinations or ophthalmic surgeries to enable a better view of the retina, optic nerve, and other internal structures of the eye. Mydriasis is important for diagnosing eye conditions like cataracts, glaucoma, and retinal diseases, as well as for performing surgeries such as cataract removal and refractive surgeries. While pupil dilation is a temporary condition, it can also be a symptom of certain medical issues or neurological disorders.

Get a Free sample for the Mydriasis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Mydriasis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mydriasis Epidemiology Segmentation:
The Mydriasis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Mydriasis
• Prevalent Cases of Mydriasis by severity
• Gender-specific Prevalence of Mydriasis
• Diagnosed Cases of Episodic and Chronic Mydriasis

Download the report to understand which factors are driving Mydriasis epidemiology trends @ Mydriasis Epidemiology Forecast
https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Mydriasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mydriasis market or expected to get launched during the study period. The analysis covers Mydriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Mydriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mydriasis Therapies and Key Companies
• RYZUMVI (Phentolamine Ophthalmic Solution 0.75%): Viatris/Ocuphire Pharma
• MYDCOMBI: Eyenovia
• OMIDRIA: Rayner Surgical/Omeros
• MydCombi: Eyenovia Inc.
• CTO0303-A: Taejoon Pharmaceutical Co., Ltd.

Discover more about therapies set to grab major Mydriasis market share @ Mydriasis Treatment Landscape
https://www.delveinsight.com/sample-request/mydriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Mydriasis Market Drivers
• Increasing Prevalence of Eye Conditions
• Technological Advancements
• Aging Population
• Increased Awareness of Eye Health
• Surge in Ophthalmic Surgeries

Mydriasis Market Barriers
• High Cost of Treatment
• Side Effects of Mydriatic Agents
• Limited Availability in Low-Resource Settings
• Competition from Alternative Therapies
• Stringent Regulatory Approval

Scope of the Mydriasis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others
• Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others
• Mydriasis Therapeutic Assessment: Mydriasis current marketed and Mydriasis emerging therapies
• Mydriasis Market Dynamics: Mydriasis market drivers and Mydriasis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Mydriasis Unmet Needs, KOL's views, Analyst's views, Mydriasis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.